 |
| Health News > FDA Approves New Treatment for Chronic Lymphocytic Leukemia | 
|
ADVERTISEMENT | ADVERTISE WITH US
Health News Videos
The Importance of Monitoring Vitamin D Status in the U.S.
Dr. Howard Nash
The Importance of Monitoring Vitamin D Status in the U.S.
Dr. Howard Nash
The NIH Common Fund's Human Microbiome Project
Top News
Subscribe to this feed:
« Back
Via FDA Press - The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. Arzerra is approved for patients with CLL whose cancer is no longer being controlled by other forms of chemotherapy. CLL primarily affects people older than 50 and arises from a group of white blood cells known as B-cells that are part of the body's immune system.
Each year, about 16,000 people are diagnosed with CLL and about 4,400 people die from the disease.Arzerra is a monoclonal antibody, a type of biotechnology product. Antibodies that occur in nature are produced by the immune system in response to invaders. Arzerra binds to a specific protein found on the surface of both normal and malignant B cells, making the cells more susceptible to immune system attack.Â
The product was approved under the FDAâ??s accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs. Products may receive accelerated approval based on a surrogate endpoint, such as a reduction in the size of the tumor or decrease in the number of cancerous white cells or in an enlarged spleen or lymph nodes.
These indirect measures for clinical outcomes are considered reasonably likely to predict that the drug will allow patients to live longer or with fewer side effects of a disease.â??The approval of Arzerra illustrates FDA's commitment to using the accelerated approval process to approve drugs for patients who have limited therapeutic options,â?? said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.
The accelerated approval process requires further study of the drug. The manufacturer is currently conducting a clinical trial in CLL patients to confirm that the addition of Arzerra to standard chemotherapy delays the progression of the disease.Arzerra's effectiveness was evaluated in 59 patients with CLL whose disease no longer responded to the available therapies.The productâ??s safety was evaluated in 181 patients in two studies in patients with cancer.
Common side effects included a decrease in normal white blood cells, pneumonia, fever, cough, diarrhea, lower red blood cell counts, fatigue, shortness of breath, rash, nausea, bronchitis and upper respiratory tract infections.The most serious side effects of Arzerra are increased chance of infections, including progressive multifocal leukoencephalopathy (PML), a brain infection that is generally fatal.
Patients at high risk for Hepatitis B should be screened before being treated with Arzerra. Patients with evidence of inactive hepatitis should be monitored for re-activation of the infection during and after completing treatment.Arzerra is manufactured by London-based GlaxoSmithKline.
Source: http://www.fda.gov/NewsEvents/What’sNewByTopic/Newsroom/PressAnnouncements/ucm187966.htm
FDA Approves New Treatment for Chronic Lymphocytic Leukemia
| Oct 27th 2009 | Drugs Cancer Leukemia |
Via FDA Press - The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. Arzerra is approved for patients with CLL whose cancer is no longer being controlled by other forms of chemotherapy. CLL primarily affects people older than 50 and arises from a group of white blood cells known as B-cells that are part of the body's immune system.
Each year, about 16,000 people are diagnosed with CLL and about 4,400 people die from the disease.Arzerra is a monoclonal antibody, a type of biotechnology product. Antibodies that occur in nature are produced by the immune system in response to invaders. Arzerra binds to a specific protein found on the surface of both normal and malignant B cells, making the cells more susceptible to immune system attack.Â
The product was approved under the FDAâ??s accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs. Products may receive accelerated approval based on a surrogate endpoint, such as a reduction in the size of the tumor or decrease in the number of cancerous white cells or in an enlarged spleen or lymph nodes.
These indirect measures for clinical outcomes are considered reasonably likely to predict that the drug will allow patients to live longer or with fewer side effects of a disease.â??The approval of Arzerra illustrates FDA's commitment to using the accelerated approval process to approve drugs for patients who have limited therapeutic options,â?? said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.
The accelerated approval process requires further study of the drug. The manufacturer is currently conducting a clinical trial in CLL patients to confirm that the addition of Arzerra to standard chemotherapy delays the progression of the disease.Arzerra's effectiveness was evaluated in 59 patients with CLL whose disease no longer responded to the available therapies.The productâ??s safety was evaluated in 181 patients in two studies in patients with cancer.
Common side effects included a decrease in normal white blood cells, pneumonia, fever, cough, diarrhea, lower red blood cell counts, fatigue, shortness of breath, rash, nausea, bronchitis and upper respiratory tract infections.The most serious side effects of Arzerra are increased chance of infections, including progressive multifocal leukoencephalopathy (PML), a brain infection that is generally fatal.
Patients at high risk for Hepatitis B should be screened before being treated with Arzerra. Patients with evidence of inactive hepatitis should be monitored for re-activation of the infection during and after completing treatment.Arzerra is manufactured by London-based GlaxoSmithKline.
Source: http://www.fda.gov/NewsEvents/What’sNewByTopic/Newsroom/PressAnnouncements/ucm187966.htm
Related articles
- FDA Approves New Treatment Jevtana (cabazitaxel) for Advanced Prostate Cancer
- Vitamin D Status is Not Associated with Risk for Less Common Cancers
- Markers on Human Breast Cancer Cells Linked to Development of an Aggressive Form of the Cancer
- FDA Approves Provenge (sipuleucel-T) for Men with Advanced Prostate Cancer
- Trends Suggest an Increase in Cancers of the Lower Stomach for Younger Whites in U.S.
- Expression of Proteins Linked to Poor Outcome in Women with Ovarian Cancer
- Pathways that Can Repair Brca1 Breast Cancer Gene Mutation Clarified in Mice
- Information on Life after Cancer Now Available on NIHSeniorHealth.gov
- Abnormal Glycoprotein Antibodies Identified as Possible Biomarkers for Cancer
- FDA Approves Rituxan (Rituximab) to Treat Chronic Lymphocytic Leukemia
Add your own comments
Comments:
No commentsHealth Resource Centers
|
Copyright 2009-2010 Emma Concepts, Inc. All rights reserved. |
About us & FAQ |
Terms of Service |
Privacy Policy |
Advertise
Healthimize.com’s content is for educational purposes only and this page and other pages on Healthimize do not contain medical advice. The information on this website is not a substitute for professional medical advice. Users further agree to abide by the terms of service. Trademarks are properties of their respective owners. |